Published in Pharma Law Weekly, August 17th, 2004
"Safety, reactogenicity and immunogenicity of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (Infanrix hexa) was assessed when used for primary vaccination at 3, 4, and 5 months of age (n=2,163), compared to the separate administration of DTPa-IPV/Hib and HBV vaccines (n=720)," researchers in Germany report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly